A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

CompletedOBSERVATIONAL
Enrollment

217

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

July 31, 2014

Conditions
Breast Cancer
Trial Locations (7)

Unknown

Consorci Sanitari de Terrassa, Barcelona

Corporacio Sanitaria Parc Tauli, Barcelona

Hospital U. Vall D'Hebron, Barcelona

Hospital U. Arnau de Vilanova, Lleida

Hospital G.U. Gregorio Maranon, Madrid

Hospital Quirón Madrid, Madrid

Hospital U. 12 de Octubre, Madrid

All Listed Sponsors
collaborator

Cedar Associates LLC

OTHER

collaborator

Illumina, Inc.

INDUSTRY

collaborator

Grupo Espanol de Investigacion del Cancer de Mama

OTHER

collaborator

Spanish Breast Cancer Research Group

OTHER

collaborator

Hospital General Universitario Gregorio Marañon

OTHER

collaborator

Vall d'Hebron Institute of Oncology

OTHER

lead

NanoString Technologies, Inc.

INDUSTRY